Image

Epidemiological Study on Community Acquired Pneumonia

Epidemiological Study on Community Acquired Pneumonia

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The main objective of this study is to investigate prevalence and risk factors for community-acquired pneumonia (CAP) and its interaction with comorbidities in an unselected group of adult patients receiving outpatient and inpatient care. In addition, information on HIV as a risk factor for CAP and on CAP in immunocompromised patients is collected.

Description

The CAPNETZ study is a prospective, multicenter observational study investigating community-acquired pneumonia (CAP). Patients are recruited from outpatient and inpatient settings at hospitals and from primary care physicians (primarily specialists) and are followed for a period of six months. All CAP patients who meet the inclusion and exclusion criteria, consent to participate, and in whom the presence of a newly developed, community-acquired pneumonia can be verified are invited to participate. The baseline examination includes a detailed medical history, medication history, and a physical examination to record clinical and vital signs. In addition, the results of routine clinical imaging are documented, and biosamples (blood, urine, and respiratory specimens) are collected for clinical chemistry and microbiological analysis. Further in-person visits to document the course of the disease and treatment, including the collection of additional blood samples, take place 3 and 7 days after study enrollment. Twenty-eight days after enrollment, the patient's health status, treatment course, and complications are assessed by telephone. Finally, after 180 days, a telephone survey is conducted to determine the patient's whereabouts and survival status. Apart from the collection of biomaterials, no interventions are required or planned; physicians treat their patients as they normally would.

Eligibility

Inclusion Criteria:

  • age ≥ 18
  • infiltrate on chest X-ray
  • further Inclusion criteria (at least one must apply): cough or purulent sputum or pathologic lung auscultation (crackles) or fever

Exclusion Criteria:

  • Hospitalization lasting longer than 48 hours prior to the diagnosis of the current pneumonia
  • Newly diagnosed, active pulmonary tuberculosis within the last 2 months

Study details
    Community Acquired Pneumonia

NCT02139163

Capnetz Stiftung

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.